BioVaxys Technology (FRA:5LB) Days Payable : 0.00 (As of Oct. 2024)

View and export this data going back to 2020. Start your Free Trial

What is BioVaxys Technology Days Payable?

BioVaxys Technology's average Accounts Payable for the three months ended in Oct. 2024 was €1.03 Mil. BioVaxys Technology's Cost of Goods Sold for the three months ended in Oct. 2024 was €0.00 Mil.

The historical rank and industry rank for BioVaxys Technology's Days Payable or its related term are showing as below:

FRA:5LB's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 123.485
* Ranked among companies with meaningful Days Payable only.

BioVaxys Technology's Days Payable stayed the same from Oct. 2023 (0.00) to Oct. 2024 (0.00). stayed the same

BioVaxys Technology Days Payable Historical Data

The historical data trend for BioVaxys Technology's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioVaxys Technology Days Payable Chart

BioVaxys Technology Annual Data

Trend

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Oct24

Days Payable

Get a 7-Day Free Trial

BioVaxys Technology Quarterly Data
	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24
Days Payable	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of BioVaxys Technology's Days Payable

For the Biotechnology subindustry, BioVaxys Technology's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioVaxys Technology's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioVaxys Technology's Days Payable distribution charts can be found below:

* The bar in red indicates where BioVaxys Technology's Days Payable falls into.

Save Embed

;

Save Embed

;

BioVaxys Technology Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

BioVaxys Technology's Days Payable for the fiscal year that ended in Oct. 2024 is calculated as

	Days Payable (A: Oct. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Oct. 2023 )	+	Accounts Payable (A: Oct. 2024 ))	/	count )	/	Cost of Goods Sold (A: Oct. 2024 )	*	Days in Period
=	( (1.834	+	1.039)	/	2 )	/	0	*	365
=	1.4365					/	0	*	365
=	N/A

BioVaxys Technology's Days Payable for the quarter that ended in Oct. 2024 is calculated as:

	Days Payable (Q: Oct. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jul. 2024 )	+	Accounts Payable (Q: Oct. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Oct. 2024 )	*	Days in Period
=	( (1.016	+	1.039)	/	2 )	/	0	*	365 / 4
=	1.0275					/	0	*	365 / 4
=	N/A

BioVaxys Technology Days Payable Related Terms

Thank you for viewing the detailed overview of BioVaxys Technology's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

BioVaxys Technology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVaxys Technology Corp (FRA:5LB) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

BVAXF:USA BIOV:Canada

Address

146 Thirtieth Street, Suite 100, Etobicoke, ON, CAN, M8W 3D4

Website

https://www.biovaxys.com

BioVaxys Technology Corp is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The company's clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix 'neoantigen' tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer.

BioVaxys Technology Headlines

No Headlines